FDA在一份公告中提到，累积数据表明，PD-L1蛋白质的表达水平可以被用来预测某些胃癌、胃食管结合部癌症和食管鳞状细胞癌患者使用免疫检查点抑制剂的疗效。然而，像默沙东的Keytruda和百时美施贵宝的Opdivo这样的重磅药物已经获准用于更广泛的患者群体，不考虑PD-L1的状态。

Accord BioPharma, the speciality division of Intas Pharmaceuticals, has received US Food and Drug Administration (FDA) ...

For patients with breast cancer, moderate hypofractionation (MHF) shows an improved safety profile, cosmesis, and quality of ...

The guidance is geared towards sponsors who conduct oncology therapy trials in more than one country under a single protocol.

Isatuximab (Sarclisa) with bortezomib, lenalidomide, and dexamethasone (VRd) is now an approved option for adults who cannot ...

Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2 ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $50.17, ...

In a report released today, Joon Lee from Truist Financial assigned a Buy rating to Corcept Therapeutics (CORT – Research Report). The ...

The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety profile consistent with ...

In a report released yesterday, Sachin Jain from Bank of America Securities reiterated a Buy rating on Genmab A/S (0MGB – Research ...

The average readability of informed consent forms of federally funded clinical trials exceeds the reading comprehension ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the exclusive worldwide license agreement with Sanofi announced on ...